Substance Use Disorder Drug Pipeline — PatSnap Eureka
Substance Use Disorder Drug Pipeline: OUD, AUD, StUD & CUD
A comprehensive analysis of pharmacological and emerging therapeutic modalities across opioid, alcohol, stimulant, and cannabis use disorders — from approved MOUD agents to preclinical D3R compounds, CB1R modulators, anti-addiction vaccines, and genomics-driven precision medicine.
A Chronic, Relapsing Brain Disorder Across Four Indications
Substance use disorders (SUDs) represent a global public health crisis characterised by chronically relapsing disease biology, high comorbidity burden, and alarming overdose mortality — particularly in the context of the ongoing opioid epidemic and expanding cannabis legalization. Retrieved results consistently characterise SUD as a chronic, relapsing brain disorder rooted in dysregulation of reward circuitry, neurotransmitter homeostasis, and executive function.
Key neurobiological systems implicated across all four SUD subtypes include dopaminergic, glutamatergic, GABAergic, opioidergic, serotonergic, and endocannabinoid pathways. A shared genetic addiction risk factor has been identified in large-scale genome-wide association studies (GWAS) encompassing over 1 million subjects, with the PDE4B gene (dopamine regulation) reaching genome-wide significance as a cross-trait vulnerability locus — research conducted at Indiana University School of Medicine.
For opioid use disorder (OUD), the µ-opioid receptor is the primary pharmacological target, with methadone, buprenorphine, and naltrexone constituting the established MOUD triad. For stimulant use disorder (StUD) — primarily cocaine and methamphetamine — dopamine D3R signalling, prefrontal hypoactivation, and glutamate homeostasis disruption are highlighted as key mechanistic nodes. The PatSnap life sciences platform enables deep exploration of these target landscapes across the published literature and patent record.
For cannabis use disorder (CUD), cannabinoid receptor 1 (CB1R) is the primary molecular target, while for alcohol use disorder (AUD), multiple targets are implicated including NMDA glutamate receptors, opioid receptors, GABA systems, and intracellular GO/STOP signalling pathways. Research from NIDA and NIAAA provides the foundational clinical evidence base for these mechanistic insights.
Nine Pharmacological Approaches Across the SUD Pipeline
From approved opioid receptor agonist/antagonist therapies to preclinical D3R compounds, CB1R modulators, anti-addiction vaccines, and psychedelics — the SUD pipeline spans a wide range of mechanistic strategies and development stages.
Opioid Receptor Agonist/Antagonist Pharmacotherapy
Methadone (full µ-opioid agonist), buprenorphine/naloxone (partial agonist), and extended-release injectable naltrexone (antagonist) form the MOUD backbone. Novel long-acting injectable and implantable buprenorphine formulations address adherence and diversion risks associated with sublingual self-administration. Research from Icahn School of Medicine at Mount Sinai and University of Pennsylvania highlights these delivery advances. PatSnap life sciences tools support landscape analysis of delivery innovation.
ApprovedApproved AUD Pharmacotherapies: Disulfiram, Naltrexone, Acamprosate, Nalmefene
Three FDA-approved agents for AUD are consistently identified: disulfiram (aldehyde dehydrogenase inhibition), naltrexone (opioid receptor antagonist), and acamprosate (NMDA receptor modulator). Nalmefene holds European regulatory approval. Retrieved results characterise these agents as modestly effective with limited uptake due to side effects and adherence challenges, per research from Women's Clinic Lucerne and University of Victoria.
ApprovedDopamine D3 Receptor-Targeted Compounds
D3R-selective antagonists and partial agonists represent a non-opioid pharmacotherapy strategy for OUD and cocaine use disorder. NIDA-IRP describes compound (S)-ABS01-113 as a potent (EC₅₀ = 7.6 nM), highly selective D3R partial agonist with 55% intrinsic efficacy, tested in animal models of opioid seeking. Wake Forest School of Medicine describes broader D3R antagonist/partial agonist profiles in rodent reinstatement models of cocaine abuse.
PreclinicalCB1 Receptor Modulators & Cannabidiol
Two CB1R-targeting strategies emerge: neutral CB1R antagonists as next-generation replacements for rimonabant (which failed due to psychiatric adverse effects), and cannabidiol (CBD) — a non-psychoactive phytocannabinoid with pleiotropic receptor activity including CB1R modulation, TRPV1 agonism, 5-HT₁A partial agonism, and GPR55 antagonism. CBD's FDA-approved (Epidiolex) status provides a regulatory entry point. Clinical trials for CBD across multiple SUD subtypes are registered in ClinicalTrials.gov and EU registries.
Early ClinicalGlutamate-Targeting Agents: Ketamine & N-Acetylcysteine
Glutamatergic dysregulation is a common neuropathological substrate across SUD subtypes. Ketamine (NMDA receptor antagonist) is evaluated in seven completed human studies across alcohol, cocaine, heroin, and other SUD populations per a systematic review from Medical University of South Carolina. N-acetylcysteine (NAC) reduces drug-seeking behaviour via cystine-glutamate exchanger (xCT/SLC7A11) modulation, reducing glutamate spillover in the nucleus accumbens.
Early ClinicalImmunotherapy & Anti-Addiction Vaccines
Immunotherapy targets the drug molecule itself via hapten conjugation — generating antibodies that sequester circulating drug molecules and prevent CNS penetration. Nicotine and cocaine vaccines have progressed to Phase 3 clinical trials per retrieved results from VA Connecticut Healthcare System/Yale and University of Medicine, Bucharest; neither is currently approved. Innovative design strategies include nanoparticle carriers, synthetic haptens, and novel adjuvants to improve immunogenicity — identified as the primary obstacle to approval.
Phase 3 CompletedSerotonergic Hallucinogens & Psychedelics
A resurgent "psychedelic renaissance" encompasses LSD, psilocybin, ketamine, ibogaine, MDMA, DMT, mescaline, and salvinorin A. Evidence is characterised as preliminary and observational/early-phase clinical for most agents. Specific applications highlighted include psilocybin and LSD for AUD, ketamine across multiple SUD subtypes. Psychedelics are proposed to act through serotonin 5-HT₂A receptor agonism and possibly neuroplasticity promotion, per research from Universidade Federal de São Paulo and Yale University School of Medicine.
Early ClinicalStimulant Substitution & Methylphenidate
For stimulant use disorders, two approaches are described: high-dose stimulant substitution as a harm reduction strategy analogous to opioid agonist therapy; and methylphenidate, leveraging the documented overlap between ADHD and SUD via shared prefrontal hypoactivation, impaired cognitive control, and hyperactive phasic dopaminergic neurotransmission. Clinical trial data on methylphenidate for SUD are referenced by Maastricht University (2023). No FDA approval for stimulant use disorder pharmacotherapy has been confirmed.
InvestigationalPPAR Agonists
Peroxisome proliferator-activated receptor (PPAR) agonists — specifically PPAR-α and PPAR-γ isoforms — are identified as candidates for reducing positive and negative reinforcing properties of ethanol, nicotine, and opioids. Preclinical animal model evidence is described as robust by University of Toronto (2020); however, human evidence is limited and less promising, with no published human trials for AUD as of the publication date.
PreclinicalMolecular Targets & Development Stage Distribution
Visualising the key molecular targets and clinical maturity signals identified across the SUD drug pipeline dataset.
Key Molecular Targets by SUD Indication
Primary pharmacological targets implicated across OUD, AUD, StUD, and CUD based on retrieved literature.
Pipeline Stage Distribution Across 9 Modalities
Clinical development stage of each therapeutic modality identified in the SUD pipeline dataset.
High-Priority Druggable Nodes Across SUD Biology
Retrieved results identify convergent molecular targets spanning receptor pharmacology, intracellular signalling, nuclear receptors, and genomics — many amenable to cross-indication pharmacological targeting.
µ-Opioid Receptor (OPRM1)
The central target for OUD pharmacotherapy. Full agonism (methadone), partial agonism (buprenorphine), and antagonism (naltrexone) are all validated. Genetic variants (e.g., OPRM1 A118G) contribute to treatment response heterogeneity. Agonist and partial agonist maintenance therapies outperform psychosocial treatment alone per retrieved results.
Dopamine D3 Receptor (DRD3)
Implicated in both OUD and StUD. Preclinical data from NIDA-IRP and Wake Forest School of Medicine describe D3R-selective partial agonists and antagonists reducing cue-, drug-, and stress-induced reinstatement of opioid and cocaine seeking. Compound (S)-ABS01-113: EC₅₀ = 7.6 nM, 55% intrinsic efficacy — establishing D3R as a high-priority non-opioid target.
CB1R & Endocannabinoid System (ECS)
CB1R mediates rewarding and motivational properties of multiple substances. ECS biomarkers — including endocannabinoid levels and CB1R expression — are described as diagnostic and therapeutic monitoring tools across SUD subtypes by Instituto de Salud Carlos III. CBD's receptor mechanisms include CB1R modulation, TRPV1 agonism, 5-HT₁A partial agonism, and GPR55 antagonism per NIDA-IRP preclinical data.
DARPP-32 (PPP1R1B) & PDE4B
DARPP-32, identified by University of Nottingham, is a convergence node for dopaminergic and other signalling cascades in addiction pathophysiology across multiple substances. PDE4B reached genome-wide significance in the largest addiction GWAS retrieved (N > 1 million, Indiana University School of Medicine), suggesting dopamine-cAMP regulation as a cross-trait vulnerability factor amenable to pharmacological targeting.
Convergent Strategies Shaping the Next Generation of SUD Therapeutics
Retrieved results signal several convergent directions driving the future of SUD drug development — from transdiagnostic approaches to precision medicine frameworks.
Key Research Institutions Driving SUD Innovation
All retrieved records are academic literature — no patent assignees were identified. Innovation activity is concentrated in U.S. federal institutes, academic medical centres, and European research consortia.
| Institution | Region | Primary Focus Area | Key Contribution |
|---|---|---|---|
| NIDA Intramural Research Program (NIDA-IRP) | USA — Federal | OUD, CUD, StUD | D3R-selective compounds (S)-ABS01-113, CB1R neutral antagonists, CBD receptor mechanisms |
| Indiana University School of Medicine | USA — Academic | Cross-SUD Genomics | GWAS of >1 million subjects identifying PDE4B as cross-trait addiction vulnerability locus |
| Yale University School of Medicine | USA — Academic | AUD, OUD, Novel Pharmacology | Multiple contributions across abuse-liability pharmacology, immunotherapy, psychedelics |
| University of Pennsylvania, Perelman SOM | USA — Academic | OUD, Cocaine Use Disorder | OUD treatment advances and cocaine use disorder pharmacotherapy |
| Medical University of South Carolina | USA — Academic | AUD, StUD, OUD | Systematic review of ketamine across 7 completed human SUD studies |
| Instituto de Salud Carlos III / RETICS | Spain — European | CUD, Multi-SUD | ECS biomarkers and CBD for SUD; multiple publications on endocannabinoid monitoring |
| Maastricht University | Netherlands — European | StUD, ADHD-SUD | Methylphenidate transdiagnostic perspective for SUD (2023) |
| Aarhus University, Centre for Alcohol and Drug Research | Denmark — European | CUD, Youth Populations | Cannabinoid-based treatment for CUD including synthetic THC and CBD RCTs |
Substance Use Disorder Drug Pipeline — key questions answered
Methadone (full µ-opioid agonist), buprenorphine and buprenorphine/naloxone (partial agonist), and extended-release injectable naltrexone (antagonist) constitute the established medication-assisted treatment (MOUD) triad for OUD. Extended treatment duration and co-administration with psychosocial support maximise efficacy.
No FDA-approved pharmacotherapy for stimulant use disorder (cocaine or methamphetamine) has been confirmed in retrieved results. Stimulant medications (methylphenidate, amphetamine) and modafinil have clinical trial evidence for reduced cravings and increased abstinence specifically in cocaine use disorder but remain investigational for this indication.
Dopamine D3 receptor (D3R) dysregulation is emerging as a secondary pharmacological target for OUD and stimulant use disorder. NIDA-IRP and Wake Forest School of Medicine describe D3R-selective partial agonists and antagonists — including compound (S)-ABS01-113 (EC₅₀ = 7.6 nM, 55% intrinsic efficacy) — reducing cue-, drug-, and stress-induced reinstatement of opioid and cocaine seeking in preclinical models.
Nicotine and cocaine vaccines have progressed to Phase 3 clinical trials per retrieved results; neither is currently approved. Immunogenicity limitations are identified as the primary obstacle. Innovative design strategies include nanoparticle carriers, synthetic haptens, and novel adjuvants to improve immunogenicity.
A shared genetic addiction risk factor has been identified in large-scale genome-wide association studies (GWAS) encompassing over 1 million subjects. The PDE4B gene (dopamine regulation) reached genome-wide significance as a cross-trait vulnerability locus across multiple substance use disorders.
No approved pharmacotherapy for cannabis use disorder has been identified in retrieved results. Placebo-controlled RCTs of synthetic THC show reduction in withdrawal symptoms but not cannabis use cessation. CBD clinical trials are described as ongoing. Neutral CB1R antagonists are in preclinical development as next-generation candidates.
PatSnap Eureka searches patents and research literature to answer instantly.